Research groups from DTU are participating in two interdisciplinary projects that receive millions in funding from
the Novo Nordisk Foundation.The Novo Nordisk Foundation supports four biomedicine and biotechnology research projects with a total of DKK 60 million. Research groups DTU are participating in two of the projects.
Treatment of Parkinson's disease and depression
Professor Lars Kai Hansen, DTU Compute, is participating in one of the projects which focuses on brain disorders, such as Parkinson's disease and depression which can be treated with electro-magnetic brain stimulation. Traditionally, this area has not taken into account the current nervous system or the state of the brain. In the research project, the stimulation of the brain will be based on measurement and modelling of the current condition of the treated brain, making the treatment much more targeted and effective.
Effective cancer treatment
In the other project, DTU Nanotech is represented by Professor Thomas Andresen. The focus of the project is to develop a new type of biotechnologically modified antibodies and nanoparticles that have an improved ability to deliver drugs into cells and cancer cells. This new type of antibodies can help to further reduce the effective dose and side effects from chemotherapy. In addition, the project group will also examine the antibodies in the treatment of inflammatory diseases.
Each project is allocated funding of DKK 15 million over a three-year period.
The funding from the
Novo Nordisk Foundation comes from a special programme—Novo Nordisk Foundation Interdisciplinary Synergy Programme—the purpose of which is to provide support for innovative, risky, interdisciplinary research for biomedical and/or biotechnological application.